国产伦乱,一曲二曲欧美日韩,AV在线不卡免费在线不卡免费,搞91AV视频

伊馬替尼治療糖皮質(zhì)激素耐藥慢性移植物抗宿主病療效分析

發(fā)布時間:2018-01-16 02:03

  本文關(guān)鍵詞:伊馬替尼治療糖皮質(zhì)激素耐藥慢性移植物抗宿主病療效分析 出處:《浙江大學(xué)》2017年碩士論文 論文類型:學(xué)位論文


  更多相關(guān)文章: 異基因造血干細胞移植 糖皮質(zhì)激素耐藥慢性移植物抗宿主病 伊馬替尼 免疫抑制治療


【摘要】:目的:分析異基因造血干細胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)后糖皮質(zhì)激素耐藥慢性移植物抗宿主病(steroid-refractory chronic graft-versus-hostdisease,SRcGVHD)的臨床特點,并探討伊馬替尼作為二線治療的療效及安全性。方法:回顧性分析2012年6月至2015年06月在我中心接受allo-HSCT 264例患者的臨床資料。對其中14例累及皮膚、肺、眼睛、口腔、肝臟、胃腸道等糖皮質(zhì)激素耐藥慢性移植物抗宿主病患者,加用伊馬替尼300mg/d二線治療,根據(jù)2014年NIH標準對cGVHD的總體療效及各個器官反應(yīng)進行評價。結(jié)果:14例糖皮質(zhì)激素耐藥cGVHD患者在接受移植后中位時間為25個月時,加用伊馬替尼300mg/d治療,評估3月療效獲得64.3%總體反應(yīng)率(Overall Response Rate,ORR),尚無患者獲得完全緩解,至6月時ORR上升至75.0%,CR率約為16.7%,其中皮膚、肺部、眼睛、口腔、關(guān)節(jié)、肝臟的ORR分別為50.0%、71.4%、100%、85.7%、100%、100%,相應(yīng)的 CR 率分別為 25.0%、14.3%、60.0%、71.4%、100%、100%。中位隨訪33個月,約50%患者可減少免疫抑制劑的維持劑量,并有1例患者完全撤藥。在伊馬替尼治療期間未發(fā)生嚴重的藥物相關(guān)性不良反應(yīng)。結(jié)論:伊馬替尼治療糖皮質(zhì)激素耐藥慢性移植物抗宿主病具有一定的臨床療效,且耐受性可,安全性佳,具有一定的臨床應(yīng)用前景。
[Abstract]:Objective: to analyze allogeneic hematopoietic stem cell transplantation. Chronic graft-versus-host disease with glucocorticoid resistance after allo-HSCT. Steroid-refractory chronic graft-versus-hostdisease. Clinical features of SRcGV HD. To evaluate the efficacy and safety of imatinib as a second line therapy methods: to retrospectively analyze the efficacy and safety of allo-HSCT in our center from June 2012 to June 2015. Clinical data of 264 patients. 14 of them involved skin. Patients with chronic graft-versus-host disease with glucocorticoid resistance, including lung, eyes, mouth, liver, gastrointestinal tract, and other glucocorticoids were treated with imatinib 300mg / d second-line therapy. According to NIH standard in 2014, the overall efficacy and organ response of cGVHD were evaluated. Results:. Fourteen patients with glucocorticoid resistant cGVHD received a median time of 25 months after transplantation. An additional 300mg / d of imatinib was used to assess the overall response rate of 64.3% Response / ORR in March. By June, ORR had risen to 75.0% and the CR rate was about 16.7.The ORR of skin, lungs, eyes, mouth, joints and liver were 50.0%, respectively. The corresponding CR rate was 25.0% and 14.30.50%, 71.4% and 100%, respectively. A median follow-up of 33 months showed that about 50% patients could reduce the maintenance dose of immunosuppressants. There was no serious adverse drug reaction during the treatment of imatinib. Conclusion:. Imatinib has a certain clinical effect in the treatment of glucocorticoid resistant chronic graft-versus-host disease. It has good tolerance and safety, and has a certain clinical application prospect.
【學(xué)位授予單位】:浙江大學(xué)
【學(xué)位級別】:碩士
【學(xué)位授予年份】:2017
【分類號】:R457.7
,

本文編號:1431032

資料下載
論文發(fā)表

本文鏈接:http://lk138.cn/shoufeilunwen/mpalunwen/1431032.html


Copyright(c)文論論文網(wǎng)All Rights Reserved | 網(wǎng)站地圖 |

版權(quán)申明:資料由用戶f8c7a***提供,本站僅收錄摘要或目錄,作者需要刪除請E-mail郵箱bigeng88@qq.com
韩国无码一到本| 日韩特黄网站| 久久天天综合精品中文字幕| 无码一区二区麻豆| 91偷拍在线| 啊啊啊嗯啊啊啊嗯嗯啊啊视频| 日本精品精品免费| 中文一区二区三区四区人妻| 大鸡吧日逼电影| 香蕉蜜臀AV在线| 日本黄色成人网| 亚洲精品视频破处| 丰满熟妇性爱av| 国产妻资源一区| 在线aa一区| 精品夜夜嗨| 亚洲国产激情社区在线| av一级一高清一高清一区完整| 亚洲精品porn| 亚洲影院一区| 国产熟女丝袜伦理 | 亚洲中文乱码成人黄色| 欧美一级一片www| 日本一道一二区高清电影| 国产精品美女被干视频| 日本高潮网站| 床戏69国产精品| 小穴插在线| 国产的又粗又猛又长又长的视频| 国产 黄色麻豆91无套内射| www.超碰人妻97免费| 久久婷婷色图片| 久久区国产精| 综合 一区 二区| 超碰成人在线之香| 日本,国产,欧美综合在线| 亚洲成人基地| 免费A级毛片视频| 亚洲区一区二| 九九九九一区二区三区四区五区| 一区二区三区 欧美 网|